NEW YORK (GenomeWeb News) – Agilent subsidiary Dako has entered into a "master framework agreement" with Eli Lilly to advance a companion diagnostic that gauges best responders for an undisclosed oncology treatment the drug maker is developing.

Although the initial focus of the collaboration will be to develop a test to accompany the specific drug, the framework agreement includes opportunities to expand the Rx/Dx partnership for other agents in Lilly's oncology pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.